Valuation: GeneNews Ltd

Market Cap 42.13L 36.91L 34.27L 31.49L 59.34L 41Cr 60.21L 4.08Cr 1.6Cr 20Cr 1.58Cr 1.55Cr 69Cr P/E 2021
-2.2x
P/E 2022 -0.39x
Enterprise Value 59.97L 52.55L 48.78L 44.83L 84.47L 58Cr 85.71L 5.81Cr 2.27Cr 28Cr 2.25Cr 2.2Cr 98Cr EV / Sales 2021
3.99x
EV / Sales 2022 1.66x
Free-Float
79.62%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer - 10/08/2016
Investor Relations Contact - -
Director TitleAgeSince
Chairman 72 01/01/2000
Chairman - 19/07/2013
Director/Board Member 92 01/01/2000
Change 5-day change 1-year change 3-year change Capi.($)
-5.00%+26.09% - - 35.06L
-4.89%-7.74%-3.35%+9.27% 4.85TCr
-0.14%-0.76%+378.26%+583.71% 3.9TCr
+0.39%+2.79%+8.23%+61.99% 3.54TCr
-1.54%-4.01%+5.95%-13.03% 3.37TCr
-0.87%-3.19%-1.27%+29.16% 2.66TCr
-1.28%-6.20% - - 1.68TCr
-0.67%-0.21%+10.55%+115.31% 1.52TCr
+1.32%+1.85%+11.40%+15.52% 1.39TCr
+0.40%-2.79%+3.58%-31.98% 1.28TCr
Average -1.23%-1.76%+51.67%+96.24% 2.69TCr
Weighted average by Cap. -1.29%-1.77%+68.45%+121.29%

Financials

2021 2022
Net sales 50.68L 44.41L 41.23L 37.88L 71.38L 49Cr 72.43L 4.91Cr 1.92Cr 24Cr 1.9Cr 1.86Cr 83Cr 37.95L 33.25L 30.87L 28.37L 53.45L 37Cr 54.24L 3.68Cr 1.44Cr 18Cr 1.42Cr 1.39Cr 62Cr
Net income -74.84L -65.57L -60.88L -55.94L -1.05Cr -72Cr -1.07Cr -7.25Cr -2.84Cr -35Cr -2.81Cr -2.75Cr -122.07Cr -1.14Cr -1Cr -92.85L -85.33L -1.61Cr -110.15Cr -1.63Cr -11Cr -4.33Cr -54Cr -4.29Cr -4.19Cr -186.19Cr
Net Debt -4L -3L -3L -3L -5L -3.56Cr -5L -35.71L -13.98L -1.74Cr -13.83L -13.54L -6.01Cr 17.84L 15.63L 14.51L 13.34L 25.13L 17Cr 25.5L 1.73Cr 67.68L 8.43Cr 66.98L 65.54L 29Cr
Logo GeneNews Ltd
StageZero Life Sciences, Ltd. is an integrated healthcare company focused on enhancing the early detection and management of cancer and chronic diseases through advanced molecular diagnostics and clinical interventions. It is developing and commercializing proprietary molecular diagnostic tests for early detection of diseases and for personalized health management, with an initial focus on cancer-related indications. The Company offers early cancer diagnostics and risk stratification via Aristotle, using messenger Ribonucleic Acid (mRNA) technology to identify the molecular signatures of multiple cancer types. Its Care Oncology Clinic provides the COC Protocol, a supervised treatment regimen designed to target multiple metabolic cancer pathways, complementing standard cancer therapies by limiting cancer cell energy supply and use. Additionally, COC offers AVRT, a physician-led telehealth program dedicated to identifying and managing early warning signs of cancer and chronic diseases.
Employees
-